Skip to content
10-Q

Quarterly Report

Allarity Therapeutics, Inc. ALLR

0001437749-26-017371

← back to feed
Filed
May 15, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 15, 2026 15.91M sh
Stock Repurchased Q1 2026 · Mar 31, 2026 $262K
Stock Repurchased Q1 2026 · Mar 31, 2025 $0
Capex Q1 2026 · Mar 31, 2026 $64K
Capex Q1 2026 · Mar 31, 2025 $0
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$4.49M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$2.69M
Short Term Debt Q1 2026 · Mar 31, 2026 $20.08M
Short Term Debt Q1 2026 · Dec 31, 2025 $0
Cash And Equivalents Q1 2026 · Mar 31, 2026 $19.81M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $14.69M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $25.2M
Stockholders Equity Q1 2026 · Mar 31, 2026 $6.92M
Stockholders Equity Q1 2026 · Dec 31, 2025 $9.83M
Stockholders Equity Q1 2026 · Mar 31, 2025 $18.67M
Stockholders Equity Q1 2026 · Dec 31, 2024 $11.81M
Current Liabilities Q1 2026 · Mar 31, 2026 $28M
Current Liabilities Q1 2026 · Dec 31, 2025 $8.43M
Total Liabilities Q1 2026 · Mar 31, 2026 $28M
Total Liabilities Q1 2026 · Dec 31, 2025 $8.43M
Current Assets Q1 2026 · Mar 31, 2026 $34.5M
Current Assets Q1 2026 · Dec 31, 2025 $17.93M
Total Assets Q1 2026 · Mar 31, 2026 $34.92M
Total Assets Q1 2026 · Dec 31, 2025 $18.26M
Eps Basic Q1 2026 · Mar 31, 2026 −$0.17
Eps Basic Q1 2026 · Mar 31, 2025 −$0.25
Sga Expense Q1 2026 · Mar 31, 2026 $1.42M
Sga Expense Q1 2026 · Mar 31, 2025 $1.63M
Rd Expense Q1 2026 · Mar 31, 2026 $1.3M
Rd Expense Q1 2026 · Mar 31, 2025 $1.4M
Net Income Q1 2026 · Mar 31, 2026 −$2.75M
Net Income Q1 2026 · Mar 31, 2025 −$2.73M
Operating Income Q1 2026 · Mar 31, 2026 −$2.69M
Operating Income Q1 2026 · Mar 31, 2025 −$3.04M
Revenue Q1 2026 · Mar 31, 2026 $25K
Revenue Q1 2026 · Mar 31, 2025 $0